In focus · trending topic

Multiple Myeloma

30 stories · following the connections

Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development

By Nasdaq OMXApr 18, 2018, 11:30 AM UTC

Actinium Pharmaceuticals to Showcase Capabilities of its AWE Technology Platform in Developing Biobetters at Upcoming AACR Annual Meeting

By Nasdaq OMXApr 11, 2018, 11:30 AM UTC

Actinium Pharmaceuticals Highlights Key Activities and Progress at BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations

By Nasdaq OMXFeb 28, 2018, 12:30 PM UTC

Actinium Appoints Anil Kapur as Chief Commercial Officer to Build Critical Commercial & Launch Capabilities Focused on Myeloablation

By Nasdaq OMXFeb 8, 2018, 1:01 PM UTC

Actinium Pharmaceuticals Announces Rights Offering

By Nasdaq OMXFeb 1, 2018, 9:06 PM UTC

Actinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research Programs

By Nasdaq OMXJan 8, 2018, 12:31 PM UTC

Actinium Pharmaceuticals Highlights Promising Data From its AWE Program Featuring a Potent Actinium-225 Labeled Daratumumab Labeled ARC or Antibody Radio-Conjugate Presented at ASH Annual Meeting

By Nasdaq OMXDec 12, 2017, 12:30 PM UTC

Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M

By Nasdaq OMXDec 11, 2017, 9:15 PM UTC